| Trial Name | Description |
| SEACRAFT-2 Mel |
Dr. Scott Ernst Not Yet Open - A randomized, open-label, phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of Naporafenib + Trametinib to physician's choice of therapy (Dacarbazine, Temoz |
| I-PACE Skin |
Dr. Scott Ernst Phase 2 Study of Imgatuzumab in Patients with Advanced CUtaneous Squamous Cell Carcinoma (I-PACE) |
| MIMic |
Dr. John Lenehan Fecal Microbial Transplantation in Combination with Immunotherapy in Melanoma Patients (MIMic) |
| MONETTE MEL |
Dr. S. Ernst A Randomized, Open Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition |
| ME.13 MEL |
Dr. John Lenehan A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP) |
| PODIUM-201 Merkel Cell |
Dr. S. Ernst A Phase 2 Study of INCMGA00012 in Participants with Metastatic Merkel Cell Carcinoma |
| COLUMBUS AD MEL |
Dr. S. Ernst Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group |